Who Is Dr. Blumenschein at MD Anderson
Dr. Blumenschein is a physician-researcher affiliated with The University of Texas MD Anderson Cancer Center, a leading cancer hospital and research campus in Houston. He focuses on thoracic and head and neck cancers, with clinical and translational work in solid tumor treatment. His roles include patient care, clinical trial leadership, and academic appointments within the MD Anderson faculty structure.
MD Anderson consistently ranks among the top cancer centers in the United States by U.S. News & World Report and is designated as a comprehensive cancer center by the National Cancer Institute. The institution operates under a large academic medical model, with revenue streams from patient care, research grants, philanthropy, and affiliated training programs.
Dr. Blumenschein's Research Focus and Funding
His research portfolio includes clinical trials in lung cancer, mesothelioma, and other thoracic malignancies, often involving immunotherapy and targeted agents. Work is supported by federal grants from the National Institutes of Health and the National Cancer Institute, as well as industry collaborations with pharmaceutical and biotech companies.
MD Anderson's total research funding exceeds several billion dollars annually, with a significant portion directed to translational science and clinical trials. Individual investigator funding depends on peer-reviewed grants, institutional support, and collaborative industry agreements, with public disclosures available through federal databases and institutional reports.
Institutional Financials and Healthcare Context
MD Anderson operates as a nonprofit academic medical center with a complex revenue mix including Medicare and Medicaid reimbursements, private insurance, self-pay, and philanthropic contributions. The institution manages large capital projects, research infrastructure, and faculty positions across multiple sites in Texas and international partnerships.
For broader context on cancer center economics and healthcare financing, see the Forbes healthcare coverage, and for regulatory filings related to large nonprofit medical centers, see the SEC database for tax-exempt organization disclosures.
Clinical Trials and Patient Access
Clinical trials at MD Anderson are overseen by institutional review boards and comply with federal regulations for human subjects research. Dr. Blumenschein's involvement in trial design and execution contributes to the pipeline of new therapies for thoracic cancers, with patient eligibility determined by protocol criteria and standard clinical assessments.
Research Collaboration and Industry Partnerships
Academic cancer centers like MD Anderson engage with pharmaceutical and device companies through sponsored research agreements, clinical trial partnerships, and scientific collaborations. These arrangements are governed by institutional conflict-of-interest policies and federal transparency requirements for financial relationships in healthcare research.
Physician Compensation and Academic Structure
Faculty compensation at academic medical centers typically includes base salary, clinical productivity incentives, and research funding components. MD Anderson publishes financial and operational data in its annual reports and IRS Form 990 filings, which are accessible through public nonprofit disclosure channels.
Key Takeaways on Dr. Blumenschein and MD Anderson
Dr. Blumenschein serves as a clinician-researcher at MD Anderson, focusing on thoracic and head and neck cancers within a major academic cancer center. The institution's financial model integrates patient care revenue, research funding, and philanthropy, supporting large-scale cancer research and treatment programs.